Skip to content
2000
Volume 14, Issue 1
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Ethionamide (ETH) is an important second-line antituberculosis drug used for the treatment of patients infected with multidrug-resistant Mycobacterium. Although ETH is a structural analogue of isoniazid (INH), both are pro-drugs that need to be activated by mycobacterial enzymes to exert their antimicrobial activity. ETH mechanism of action is thought to be identical to INH although the pathway of activation is distinct from that of INH. ETH is activated by an EthA enzyme, leading to the formation of an Soxide metabolite that has considerably better activity than the parent drug. This review comprehensively examines the aspects related with the metabolism of ETH since its discovery up to today.

Loading

Article metrics loading...

/content/journals/cdm/10.2174/138920013804545151
2013-01-01
2025-12-09
Loading full text...

Full text loading...

/content/journals/cdm/10.2174/138920013804545151
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test